Correspondence
B-Cell–Depleting Induction Therapy and Acute Cellular Rejection
N Engl J Med 2009; 360:2683-2685June 18, 2009
- Article
To the Editor:
B-cell depletion is an effective treatment for a number of autoimmune diseases in which B cells were not previously considered to be important, such as multiple sclerosis.1 In renal transplantation, acute cellular rejection has been viewed as a T-cell–dependent process, but B cells are required for alloantibody production and may also play other roles, including alloantigen presentation to T cells.2
Published data on the use of B-cell depletion at induction in nonsensitized patients undergoing organ transplantation are lacking. We conducted an open-label, randomized, controlled trial comparing rituximab, a B-cell–depleting, chimeric, anti-CD20 monoclonal antibody, with an anti-CD25 monoclonal antibody (daclizumab) as induction therapy in patients undergoing renal transplantation. We planned to recruit 120 patients, but the study was suspended after recruitment of the first 13 patients, owing to an excess incidence of acute cellular rejection in the rituximab group. Five of six patients (83%) who received rituximab had an episode of biopsy-confirmed acute rejection in the first 3 months after transplantation, as compared with one of seven patients (14%) in the daclizumab group (P=0.01) (Table 1Table 1
Immunosuppression, Acute Rejection, and Allograft Function. and Figure 1Figure 1
Increased Rate of Acute Rejection in Rituximab-Treated Patients.). All the episodes of rejection responded to intravenous methylprednisolone, and allograft function was similar in the two groups at 12 months (Table 1, and Fig. 1A in the Supplementary Appendix, available with the full text of this letter at NEJM.org). After rituximab treatment, peripheral B cells were undetectable in all patients (Fig. 1B in the Supplementary Appendix). Serum cytokines, including tumor necrosis factor α, interleukin-6, and interleukin-10, were increased after transplantation, as compared with baseline values, in some of the patients who were treated with rituximab (Fig. 2, 3, and 4 in the Supplementary Appendix).Our findings are surprising; patients who received rituximab had a rate of acute rejection that was not only higher than the rate in the control group (83% vs. 14%) but also was higher than that previously observed among patients who have not received induction therapy (35%).3 One possible explanation may be that proinflammatory cytokine release associated with B-cell depletion might prime antigen-presenting cells. A short-lived cytokine-release syndrome often occurs after administration of the first dose of rituximab4; in our study, some patients who were treated with rituximab had elevated levels of proinflammatory cytokines. However, we cannot exclude the possibility that the increased levels of cytokines were the result rather than the cause of acute rejection.
Although B cells may enhance immune responses, some B cells have immunoregulatory properties. In animal models, depletion of such B cells before disease induction can worsen autoimmunity,5 and rituximab therapy can exacerbate ulcerative colitis and psoriasis. Similarly, depletion of immunoregulatory B cells may have contributed to the increased rejection in the rituximab-treated patients.
Recipients of renal transplants in whom rituximab is administered for desensitization do not appear to be at an increased risk for acute cellular rejection. Such patients usually receive rituximab well before transplantation, and rituximab treatment is often accompanied by plasma exchange and corticosteroid therapy; thus, any associated cytokine storm would probably resolve by the time of transplantation.
B-cell depletion has emerged as a powerful treatment strategy in autoimmunity; however, our results show that this strategy should be undertaken with caution when the precise role of B cells in a disease is unclear. (EudraCT Number, 2005-001496-35.)
Menna R. Clatworthy, Ph.D., M.R.C.P.
Christopher J.E. Watson, M.D., F.R.C.S.
Gemma Plotnek, M.B., B.Chir.
Vicky Bardsley, M.B., B.Chir.
Afzal N. Chaudhry, Ph.D., F.R.C.P.
J. Andrew Bradley, Ph.D., F.Med.Sci.
Kenneth G.C. Smith, Ph.D., F.Med.Sci.
University of Cambridge School of Clinical Medicine, Cambridge CB2 2QQ, United Kingdom
kgcs2@cam.ac. uk Supported by grants from Roche Pharmaceuticals and the National Institute for Health Research Cambridge Biomedical Research Centre.
Drs. Clatworthy and Watson report receiving grants from Roche to attend scientific meetings and lecture fees from Wyeth and Astellas; Dr. Bradley, receiving grant support from Roche; and Dr. Smith, receiving consulting fees from and serving on advisory boards for Roche and GlaxoSmithKline and receiving grant support from GlaxoSmithKline. No other potential conflict of interest relevant to this letter was reported.
5 References1
Hauser SL ,Waubant E ,Arnold DL , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
Full Text | Web of Science | Medline2
Zarkhin V ,Li L ,Sarwal M . “To B or not to B?” B-cells and graft rejection. Transplantation 2008;85:1705-1714
CrossRef | Web of Science | Medline3
Vincenti F ,Kirkman R ,Light S , et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-165
Full Text | Web of Science | Medline4
Agarwal A ,Vieira CA ,Book BK ,Sidner RA ,Fineberg NS ,Pescovitz MD . Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004;4:1357-1360
CrossRef | Web of Science | Medline5
Matsushita T ,Yanaba K ,Bouaziz JD ,Fujimoto M ,Tedder TF . Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-3430
Web of Science | Medline
- Citing Articles (32)
Citing Articles
1
Vinayak Ramanath, Ravi Nistala, Kunal Chaudhary. (2012) Update on the role of rituximab in kidney diseases and transplant. Expert Opinion on Biological Therapy 12:2, 223-233
CrossRef2
E. G. Kamburova, H. J. P. M. Koenen, L. Boon, L. B. Hilbrands, I. Joosten. (2011) In Vitro Effects of Rituximab on the Proliferation, Activation and Differentiation of Human B Cells. American Journal of Transplantationno-no
CrossRef3
N. Kohei, T. Hirai, K. Omoto, H. Ishida, K. Tanabe. (2011) Chronic Antibody-Mediated Rejection Is Reduced by Targeting B-Cell Immunity During an Introductory Period. American Journal of Transplantationno-no
CrossRef4
Olivier Thaunat. (2011) Humoral immunity in chronic allograft rejection: Puzzle pieces come together. Transplant Immunology
CrossRef5
Robert R Redfield, Eduardo Rodriguez, Ronald Parsons, Kumar Vivek, Moiz M Mustafa, Hooman Noorchashm, Ali Naji. (2011) Essential role for B cells in transplantation tolerance. Current Opinion in Immunology 23:5, 685-691
CrossRef6
Valeriya Zarkhin, Minnie M. Sarwal. (2011) The coin toss of B cell in rejection and tolerance: Danger versus defense. Seminars in Immunology
CrossRef7
M. R. Clatworthy. (2011) Targeting B Cells and Antibody in Transplantation. American Journal of Transplantation 11:7, 1359-1367
CrossRef8
Martijn WF van den Hoogen, Luuk B Hilbrands. (2011) Use of monoclonal antibodies in renal transplantation. Immunotherapy 3:7, 871-880
CrossRef9
Olivier Thaunat. (2011) Pathophysiologic Significance of B-Cell Clusters in Chronically Rejected Grafts. Transplantation 92:2, 121-126
CrossRef10
Marcia Kho, Karlien Cransberg, Willem Weimar, Teun van Gelder. (2011) Current immunosuppressive treatment after kidney transplantation. Expert Opinion on Pharmacotherapy 12:8, 1217-1231
CrossRef11
Roberto Marcén. (2011) Immunosuppression and renal transplant rejection: review of current and emerging therapies. Clinical Investigation 1:6, 859-877
CrossRef12
Fred Fändrich. (2011) Tolerance in clinical transplantation: progress, challenge or just a dream?. Langenbeck's Archives of Surgery 396:4, 475-487
CrossRef13
M. Willicombe, P. Brookes, E. Santos-Nunez, J. Galliford, A. Ballow, A. Mclean, C. Roufosse, H. T. Cook, A. Dorling, A. N. Warrens, T. Cairns, D. Taube. (2011) Outcome of Patients with Preformed Donor-Specific Antibodies Following Alemtuzumab Induction and Tacrolimus Monotherapy. American Journal of Transplantation 11:3, 470-477
CrossRef14
N. Barnett, A. Dorling, N. Mamode. (2011) B cells in renal transplantation: pathological aspects and therapeutic interventions. Nephrology Dialysis Transplantation 26:3, 767-774
CrossRef15
Toshihito Hirai, Hideki Ishida, Daisuke Toki, Yuuki Miyauchi, Naoki Kohei, Shouichi Iida, Daisuke Tokita, Tomokazu Shimizu, Hiroki Shirakawa, Kazuya Omoto, Kazunari Tanabe. (2011) Comparison of the Acute Rejection Incidence Rate in Spousal Donor Transplantation Before and After Anti-CD20 Antibody (Rituximab) Protocol as Desensitization Therapy. Therapeutic Apheresis and Dialysis 15:1, 89-97
CrossRef16
Jeffrey L Platt, Shoichiro Tsuji, Marilia Cascalho. (2011) Novel functions of B cells in transplantation. Current Opinion in Organ Transplantation 16:1, 61-68
CrossRef17
R. Baker, A. Jardine, Peter Andrews. (2011) Renal Association Clinical Practice Guideline on Post-operative Care of the Kidney Transplant Recipient. Nephron Clinical Practice 118:s1, c311-c347
CrossRef18
Renaud Snanoudj, Sophie Candon, Christophe Legendre. (2010) Targeting B cells in sensitized kidney transplant patients: state of the art and future perspectives. Current Opinion in Organ Transplantation 15:6, 709-715
CrossRef19
Niloufar Safinia, Behdad Afzali, Kerem Atalar, Giovanna Lombardi, Robert I Lechler. (2010) T-cell alloimmunity and chronic allograft dysfunction. Kidney International 78, S2-S12
CrossRef20
Peter M. Eckman, Mazen Hanna, David O. Taylor, Randall C. Starling, Gonzalo V. Gonzalez-Stawinski. (2010) Management of the sensitized adult heart transplant candidate. Clinical Transplantation 24:6, 726-734
CrossRef21
Peter M Eckman. (2010) Immunosuppression in the sensitized heart transplant recipient. Current Opinion in Organ Transplantation 15:5, 650-656
CrossRef22
Toshihito Hirai, Hideki Ishida, Daisuke Toki, Yuuki Miyauchi, Naoki Kohei, Shouichi Iida, Daisuke Tokita, Tomokazu Shimizu, Hiroki Shirakawa, Kazuya Omoto, Kazunari Tanabe. (2010) Comparison of the Acute Rejection Incidence Rate in Spousal Donor Transplantation Before and After Anti-CD20 Antibody (Rituximab) Protocol as Desensitization Therapy. Therapeutic Apheresis and Dialysisno-no
CrossRef23
Behdad Afzali, Robert Lechler, Giovanna Lombardi. 2010. Graft Rejection: Immunological Suppression. .
CrossRef24
O. Thaunat, E. Morelon, T. Defrance. (2010) Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 116:4, 515-521
CrossRef25
Toshio Takagi, Hideki Ishida, Hiroki Shirakawa, Tomokazu Shimizu, Kazunari Tanabe. (2010) Evaluation of Low-Dose Rituximab Induction Therapy in Living Related Kidney Transplantation. Transplantation 89:12, 1466-1470
CrossRef26
Iñaki Sanz, F. Eun-Hyung Lee. (2010) B cells as therapeutic targets in SLE. Nature Reviews Rheumatology 6:6, 326-337
CrossRef27
Frances E. Lund, Troy D. Randall. (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nature Reviews Immunology 10:4, 236-247
CrossRef28
R. John Looney, Jennifer Anolik, Inaki Sanz. (2010) A perspective on B-cell-targeting therapy for SLE. Modern Rheumatology 20:1, 1-10
CrossRef29
Angela C Webster, Lorenn P Ruster, Richard McGee, Sandra L Matheson, Gail Y Higgins, Narelle S Willis, Jeremy R Chapman, Jonathan C Craig, Angela C Webster. 2010. Interleukin 2 receptor antagonists for kidney transplant recipients. .
CrossRef30
Ronald F Parsons, Kumar Vivek, Robert R Redfield, Thi-Sau Migone, Michael P Cancro, Ali Naji, Hooman Noorchashm. (2009) B-cell tolerance in transplantation: is repertoire remodeling the answer?. Expert Review of Clinical Immunology 5:6, 703-723
CrossRef31
(2009) More on B-Cell–Depleting Induction Therapy and Acute Cellular Rejection. New England Journal of Medicine 361:12, 1214-1216
Full Text32
Iñaki Sanz. (2009) Indications of Rituximab in autoimmune diseases. Drug Discovery Today: Therapeutic Strategies 6:1, 13-19
CrossRef
- Letters
